

**Morbidity and Drug Utilization Pattern of Integrative Medicine (Siddha medicine and Biomedicine) - A Single Center Retrospective Study of 150 Patients**Shanmugavelan Rajalakshmi^{1*}, Karunanidhi Samraj¹, Kannaiyan Nandhagopal¹, Parameswaran Sathiyarajeswaran², Kadarkarai Kanakavalli³¹Siddha Clinical Research Unit (SCRU), Tirupati, Andhra Pradesh, India²Siddha Central Research Institute (SCRI), Chennai, Tamilnadu, India³Central Council for Research in Siddha (CCRS), Chennai, Tamilnadu, India

ARTICLE INFO

ABSTRACT

Article history:

Received 21 May 2020

Revised 15 December 2021

Accepted 02 January 2022

Published online 03 February 2022

Copyright: © 2022 Rajalakshmi *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Integrative Medicine (IM) is a rapidly growing field because of increased demand, which requires further evidence-based research to provide more information on the effectiveness and safety. The aim of the study was to assess morbidity and drug utilization among patients using IM attending Siddha Clinical Research Unit (SCRU), Tirupati, India. The information obtained in the google form, which is the research database of the SCRU, Tirupati, was investigated in this study throughout the time of July to December 2019. The patient demographics, morbidities, commonly used Siddha medications, and biomedicines prescribed at the first visit were studied. Results revealed that most IM users 80 (53.3%) were males, the mean age of IM users was 56.53 years. The most common morbidities were diabetes 95 (63.3%), hypertension 29 (19.3%). Siddha medicines such as *Amukkara chooranam* 98 (65.3%), *Aavarai kudineer* 85 (56.6%), were commonly prescribed along with the biomedicine, metformin 91 (60.6%), amlodipine 62 (41.3%). Thus, the common morbidity of the IM users were diabetes and hypertension, common siddha drugs utilized were *Amukkara chooranam*, *Aavarai kudineer*, and biomedicine were metformin, amlodipine.

Keywords: Biomedicine, Drug-drug interaction, Integrative Medicine, Siddha medicine, Traditional medicine.

Introduction

Integrative Medicine (IM) is healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. It emphasizes the therapeutic relationship between practitioner and patient, it is informed by evidence, and makes use of all appropriate therapies.¹ The IM approach recently re-emerged with the expectation of providing an affordable practical resolution to the global healthcare crisis. The IM consortium, which includes Arizona, Duke, Harvard, Johns Hopkins, UCLA, and Mayo clinic in the United States, has actively argued for it as a critical component of the new healthcare system in the public interest. Many countries in Asia, Africa, Europe (Norway (Troms), Sweden (Karolinska)), Latin America, Australia and China have IM activities.² In general, IM refers to the interaction of multiple medical systems and therapies, such as allopathy and complementary and alternative medicine (CAM).^{3,4} In India, it is a common practice, that people unknowingly use one herbal medicine in their day to day life along with the prescribed biomedicine. Such practice can be attributed to their culture.

Siddha system originated in Tamilnadu, the most primordial among the AYUSH (Ayurvedha, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) systems. Siddhars, the forefathers of the Siddha system, transferred their affluent knowledge to the suffering mankind through their disciples.⁵ In Siddha medicine, there are 32 types of internal and external medicines, and it has three major subdivisions:

*Corresponding author. E mail: dr.rajibsms23@gmail.com
Tel: 9585600845

Citation: Rajalakshmi S, Samraj K, Nandhagopal K, Sathiyarajeswaran P, Kanakavalli K. Morbidity and Drug Utilization Pattern of Integrative Medicine (Siddha medicine and Biomedicine) - A Single Center Retrospective Study of 150 Patients. Trop J Nat Prod Res. 2022; 6(1):24-28. doi.org/10.26538/tjnpr/v6i1.5

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

plant, inorganic, animal product.

a. Plant products, are used as single herb and as compound formulations. The compound formulations are used in various forms such as *chooranam* (powder), *kudineer* (decoction), *mathirai* (tablet), *charu* (juice), *legium*, *manappagu* (syrup) etc.

b. Inorganic compounds (IOCs) are divided into 4 subdivisions; they are metals (ulogam)-12, minerals (karasaram)-64, hydrochemicals (uparasam)-24 and toxins (paasanam)-120. IOCs are usually made into preparations such as *parpam*, *chendhuram*, *chunnam*, *padhangam*, *kattu*, *kalangu* etc.

c. Animal products (leech, crab, monitor lizard, deer horn, elephant teeth, diary and diary derivatives, and other marine products) and their components such as teeth, bone, and egg are used.

Recently there are 3986 hospitals, 27199 Dispensaries, in AYUSH System, which includes, 291 hospitals, 848 dispensaries, in Siddha system alone. Institutionally qualified practitioners in AYUSH system are 587660, whereas in Siddha it is around 5685 practitioners.⁶ In India, doctor-population ratio (1:1,000) as said by the World Health Organization (WHO), is achieved after considering AYUSH doctors. Thus, the study on drug utilization and disease pattern in IM users serves as an effective tool for identification of combined efficacy and safety of drugs used in both 'systems'. This is the first study in literature to investigate the documentation of Integrative Medicine (Siddha and BioMedicine), as well as the morbidity and drug usage of IM users. The aim of this study is to assess morbidity and drug utilization among patients using IM attending Siddha Clinical Research Unit (SCRU), Tirupati, India.

Materials and Methods

Study design

This was a retrospective study of patients (n=150) who had used both Siddha and Biomedicine herein defined as IM users.

Data source

The information obtained in the google form, SCRUCRU, Tirupati, was investigated for this study, which included patients' age, sex, registration number, date of medical visits, drugs, diagnosis, management and treatment from July 2019 to December 2019.

Since it is a retrospective study, Institutional review board approval was not required because all personal data were kept confidential. All data analyzed were collected as part of routine diagnosis and treatment, they were not reported separately.

Statistical analysis

Data analysis included the prevalence of IM user segregated by the patient's demographic characteristics, morbidity, proportion of the first prescribed Siddha drugs and biomedicine drugs.

Results and Discussion

Demographic characters and morbidity of IM users

The IM usage differed depending on age and sex; males were high users of IM 80 (53.3%), females were fewer 70 (46.7%). The mean age of IM users was 56.53 years. No patient was reported between the ages of 0-10. Number of patients with IM in age groups of 50-60 > 60-70 > 40-50 > 70-80 > 30-40 > 20-30 = 10-20 were reported (Table 1). Male female ratio 1.14: 1. The utilization of IM increases with age; maximum users were reported in the age group of 50-60 years [45 (30%)] and 60-70 years [44 (29.3%)]. The top ranked morbidity in IM users were diabetes mellitus, hypertension, dyslipidemia and hypothyroidism (Table 2). The increase in the prevalence of non-communicable diseases, drug resistance and biomedicine complications; dissatisfaction with the outcomes of certain biomedical treatments; have intended for much attention to traditional medical systems. This has led the public to conceive the idea of integration of biomedicine with traditional Medicine. According to WHO 2021 statistics, non-communicable diseases (NCDs) claim the lives of 41 million people each year, accounting for 71% of deaths worldwide. The most common NCD is cardiovascular disease, which kills 17.9 million people each year, preceded by cancer (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). This indicates that NCDs needs to be controlled and prevented.⁷ In this study cancer was reported in three (2%) patients, this showed the demand of taking Siddha medicine along with the standard chemotherapy and in post-operative stage of cancer.

A single case study of 53-year male patient of squamous cell carcinoma- tongue, who underwent Siddha treatment, after 7 months of radiation therapy, showed an increased survival rate of about 5 years.⁸ The study on Yajna Therapy as supportive care in cancer patients for two months showed an increase in their Quality of life (QOL).⁹ The study on herbal use among cancer patients during palliative and curative chemotherapy treatment in Norway, revealed that curative patients used herbal remedies more often to counteract adverse reactions and the palliative patients used to improve their immune system.¹⁰ These findings showed that the results facilitate the use of integrative medicine in cancer palliative care.

Commonly used Siddha medicines and Biomedicines

The most prescribed Siddha medicines in IM users were *amukkara chooranam* 98 (65.3%), followed by *aavaraikudineer* 85 (56.6%), *nilavaagaichooranam* 63 (42%), *thiripalakudineer* 62 (41.3%) and the biomedicines were metformin (60.6%), amlodipine (41.3%), aspirin (15.3%), telmisartan (14.6%). (Table 3)

In India both traditional medicine and Biomedicine are regulated and supported by the Indian government. Traditional medicine is actively practiced in all AYUSH medical hospitals and in some allopathy hospital. There are two forms of IM,

- Referral between the Biomedicine practitioner and AYUSH practitioners.

- AYUSH practitioners working directly within the allopathy hospital.

In this study the first commonly prescribed Siddha medicine is *Amukkara chooranam* for pain management (Table 4) it has anti-inflammatory, anti-arthritis, immune-modulatory, anti-microbial activity. According to the annual report of SCRUCRU Tirupati 2019-2020¹¹, the first common diseases reported was osteoarthritis and it is also evident that the peoples of Andhra Pradesh was the first leading state affected by osteoarthritis in India.

Aavaraikudineer is the second commonly prescribed Siddha medicine, has anti-diabetic, anti-microbial activity. According to the Siddha classical text it can be used for both diabetes mellitus and renal dysfunction. Third most prescribed Siddha medicine is *Nilavaagai chooranam* (NVC) used as a laxative. A study reported the inadequate glycemic control increases the frequency of constipation in diabetes mellitus patients.³² Hence NVC was prescribed in addition with either *thiripala kudineer* or *aavaraikudineer*, commonly prescribed medicines for diabetes.

Thiripala kudineer the fourth most prescribed Siddha medicine along with Biomedicine, has several therapeutic activities (Table 4). Since it has anti-diabetic activity, was prescribed for diabetes and to treat complications caused by diabetes such as cardiovascular diseases, obesity, dyslipidemia etc.

In this study not only, herbal drugs some of the Herbo-mineral drugs were also prescribed, they were *silasathu parpam*, *kalnar parpam*, *arumuga chendhuram*, *ayabringa raja karpam*, *rasagandhi mezhugu*.

Table 1: Basic demographic character of IM user

| Characteristics age Years | Male n (%) | Female n (%) | Total n (%) |
|---------------------------|-------------|--------------|-------------|
| 0-10 | Nil | Nil | Nil |
| 10-20 | Nil | 2 (1.3) | 2 (1.3) |
| 20-30 | 1 | 1 (0.6) | 2 (1.3) |
| 30-40 | 7 (4.6) | 3 (2) | 10 (6.7) |
| 40-50 | 8 (5.3) | 19 (12.6) | 27 (18) |
| 50-60 | 24 (16) | 21 (14) | 45 (30) |
| 60-70 | 25 (16.6) | 19 (12.6) | 44 (29.3) |
| > 70 | 15 (10) | 5 (3.3) | 20 (13.3) |
| Total | 80 (53.3) | 70 (46.7) | 150 (100) |
| Ratio Male: Female | 1.14:1 | | |
| Mean Age | 56.53 years | | |

Table 2: Morbidity of IM users

| S. No | Diseases | No. of patients n (%) |
|-------|-------------------------|-----------------------|
| 1. | Diabetes | 95 (63.3) |
| 2. | Hypertension | 29 (19.3) |
| 3. | Hypothyroidism | 5 (3.3) |
| 4. | Psychiatric disorder | 6 (4) |
| 5. | Cardiovascular disorder | 5 (3.3) |
| 6. | Rheumatoid arthritis | 3 (2) |
| 7. | Cancer | 3 (2) |
| 8. | Epilepsy | 2 (1.4) |
| 9. | Urticaria | 2 (1.4) |

Table 3: List of Biomedicines and Siddha medicines used in IM

| S/N | Biomedicine | No. of patients n (%) | Siddha medicines | No. of patients n (%) |
|-----|---------------------|-----------------------|----------------------------------|-----------------------|
| 1. | Metformin | 91 (60.6) | <i>Amukkarachooranam</i> | 98 (65.3) |
| 2. | Amlodipine | 62 (41.3) | <i>Aavaikudineer</i> | 85 (56.6) |
| 3. | Asprin | 32 (15.3) | <i>Nilavaagaichooranam</i> | 63 (42) |
| 4. | Telmisartan | 22 (14.6) | <i>Thiripalakudineer</i> | 62 (41.3) |
| 5. | Glimipride | 21 (14) | <i>Thalisaathichooranam</i> | 46 (30.6) |
| 6. | Atorvastatin | 20 (13.3) | <i>Parangipattaimathirai</i> | 34 (22.6) |
| 7. | Levothyroxine | 19 (12.6) | <i>Silasathuparpam</i> | 41 (27.3) |
| 8. | Calcium | 12 (8) | <i>Kalnarparpam</i> | 44 (29.3) |
| 9. | Copidogrel | 8 (5.3) | <i>NerunjilKudineer</i> | 4 (2.6) |
| 10. | Vit-D12 | 8 (5.3) | <i>Elathychooranam</i> | 4 (2.6) |
| 11. | Hydrochlorothiazide | 5 (3.3) | <i>Arumugachendhuram</i> | 2 (1.3) |
| 12. | Atenolol | 4 (2.6) | <i>Ayabringarajakarpam</i> | 2 (1.3) |
| 13. | Insulin | 10 (6.6) | <i>Capsule Rasagandhimezhugu</i> | 2 (1.3) |

Table 4: Siddha medicine, ingredients, their activities used in IM

| S/N | Siddha medicines | Ingredients | Pharmacological activity |
|-----|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | <i>Thiripalakudineerchooranam</i> (Decoction powder) | Terminalia chebula, Emblica officinalis, Terminalia belerica | Stress-reducing potential ¹² , Anti-obesogenic ¹³ Anti-diabetic ¹⁴ , Anti-microbial ¹⁵ , Anti-neoplastic ¹⁶ , Antioxidant ¹⁷ , Anti-inflammatory, Anti-aging ¹⁸ |
| 2 | <i>Amukkarachooranam</i> (Powder) | Withania somnifera, Zingiber officinale, Piper nigrum Piper longum, Elettaria cardamomum Cinnamomum verum, Syzygium aromaticum Saccharum officinarum | Anti-Inflammatory, Arthralgia ¹⁹ Immuno-modulatory, Anti-microbial ²⁰ |
| 3 | <i>Aavaikudineer</i> (Decoction powder) | Cassia auriculata, Cassia fistula, Syzygium cumini Cyperus rotundus, Saussurea lappa, Terminalia arjuna Salacia reticulata | Anti-diabetic ²¹ , Anti-microbial ²² |
| 4 | <i>Nilavaagaichooranam</i> (Powder) | Cassia angustifolia, Zingiber officinale, Piper nigrum Embelia ribes | Eczema ²³ |
| 5 | <i>Thalisaathichooranam</i> (Powder) | Saussurea lappa, Piper longum, Cumimum cyminum Anethum sowa, Nigella sativa, Piper longum, Syzygium aromaticum, Myristica fragrans, Piper nigrum, Nardostachys jatamansi, Cinnamomum verum Michel champaca, Embelia ribes, Trachyspermum ammi Coriandrum sativum | Anti-oxidant ²⁴ |
| 6 | <i>Parangipattaimathirai</i> (Tablet) | Smilax china Saccharum officinarum | Anti-inflammatory, Immuno-modulatory Anti-psoriatic ²⁵ , Anti-microbial ²⁶ Anti-vitiligo ²⁷ |
| 7 | <i>Silasathuparpam</i> | Calcium sulphate dehydrate, Coldenia procumbens | Anti-urolithiatic Activity ²⁸ |
| 8 | <i>Kalnarparpam</i> | Asbestos, Aristolochia bracteolata | |
| 9 | <i>NerunjilKudineer</i> (Decoction powder) | Tribulus terrestris, Embilica officinalis, Terminalia chebula Terminalia belerica, Asteracantha longifolia, Smilax china Solanum nigrum, Cassia fistula, Foeniculam vulgare, | Nephroprotective ²⁹ Lithotriptic effect ³⁰ |

| | | | |
|----|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| | | Cucumis sativus, Lagenaris vulgaris | |
| 10 | <i>Elathychooranam</i> (powder) | Elettaria cardamomum, Cuminum cyminum Syzygium aromaticum, Glycyrrhiza glabra Emblica officinalis, Cinnamomum tamala Cinnamomum verum, Murraya koenigii Santalum album, Nardostachys jatamansi Foeniculum vulgare, Saccharum officinarum | |
| 11 | <i>Arumugachendhuram</i> | Mercuric sulphide, Magnetic oxide of iron Sulphur, Sodium baborate, Sodium chloride impure, Ferrum – Iron Aloe vera | |
| 12 | <i>Ayabringarajakarpam</i> | Iron, Citrus limon, Eclipta prostrata | |
| 13 | <i>Rasagandhimezhugu</i> | Elemental Mercury, Elementary Sulphur Mercurous chloride, Arsenic trisulphide Magnetite ore of Iron, Copper sulphate Zinc carbonate with traces of Zinc sulphate Lead monoxide and 40 other herbs | Anti-Cancer ³¹ |

These medicines are also called as higher order medicines (Peru marunthugal). The uniqueness of higher order medicine is,

- effective even in minimal dose,
- it challenges incurable diseases,
- it has increased bioavailability,
- shelf life is higher compared to plant products,
- therapeutic efficacy is high,
- Gives quick remedy.

Arumuga chendhuram is also one of the herbo-mineral drugs prescribed in this study has anti-arthritis activity (Table 4) treated by incineration process. *Chendhuram (Red oxide)* is a red-colored powder generated by burning, frying, or incineration of metallic or arsenical compounds. *Ayabrinaraja Karpam* is one of the herbo-mineral karpam (Rejuvenator) prescribed in this study indicated for anemia, dropsy etc. Karpam means rejuvenator, it is one of the distinctive therapeutic divisions in Siddha system of medicine advocated specially for rejuvenation, decreasing morbidity and increasing the life span. Nearly 108 herbs and herbo-mineral combinations are recommended for prevention of diseases and restoration of health from specific diseases. *Rasagandhi mezhugu* (RGM) is also one of the higher order medicines prescribed in this study; contains 40 herbal drugs, 8 metallic and mineral drugs, indicated for a variety of diseases. It was also tested for anti-cancer activity, HPV-positive cervical cancer cells, ME-180 and SiHa and it affected the viability of both the cells. *Silasathu parpam* has anti urolithiatic activity. In the classical text, black asphaltum is indicated for dysuria, urinary tract infection. *Kalnar parpam*, is used in all types of epilepsy, mental retardation, schizophrania, burning micturition, dysuria, spermatorrhoea.

Prospects for future studies

1. This study focus on the disease identification of IM users, which yet to be revealed. The use of IM in non-communicable diseases such as diabetes mellitus, hypertension, dyslipidemia, hypothyroidism and malignancy were more. This gives an insight into the research focus on integrative medicines utilization in major non-communicable diseases.

2. This study exploring the Siddha medicine and biomedicine utilization for diseases, will open a new path for drug-drug interaction studies. The studies on drug utilization and prescribing patterns can serve as an effective tool for investigating the clinical pharmacology to offer suggestive information to identify the effective Integrative medicine³³.

Conclusion

This study found out that the males were high users of IM, females were fewer. The mean age of IM users was 56.53 years. Maximum users were reported in the age of 50-60 years and 60-70 years. The top ranked morbidity was diabetes mellitus, hypertension, dyslipidemia and hypothyroidism. The most prescribed Siddha medicines in IM users were *amukkara chooranam*, followed by *aavarai kudineer*, *nilavaagai chooranam*, *thiripala kudineer* and the biomedicines were metformin, amlodipine, aspirin, telmisartan. These findings facilitate further research into IM, specific to disease.

Conflict of Interest

The authors declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

References

- Andrew Weil, What is Integrative Medicine?: Andrew Weil Center for Integrative Medicine [online]. [cited 2021 Apr 17]. Available from: <https://integrativemedicine.arizona.edu/about/definition.html>
- Patwardhan B. Ayurveda and integrative medicine: Riding a tiger. *J Ayurveda Integr Med.* 2010; 1(1):13-15.
- Thomas KJ, Nicholl JP, Coleman P, Thomas K. Use and expenditure on complementary medicine in England: a population based survey. *Comp Ther Med.* 2001; 9(1):2-11.
- Sawni-sikand A, Schubiner H, Thomas RL. Use of Complementary/Alternative Therapies Among Children in Primary Care Pediatrics. *Ambulatory Pediat.* 2002; 2(2):99-103.
- Tamil Nadu Dr. M.G.R Medical University, Chennai, Department of Siddha, [online]. [cited 2021 Dec 28]. Available from: <https://www.indcareer.com/tamil-nadu-dr-mgr-medical-university-chennai/Departments/department-siddha>.
- Ministry of Ayush | Home [Internet]. [cited 2021 Dec 15]. Available from: <https://dashboard.ayush.gov.in/>
- Noncommunicable diseases [Internet]. [cited 2021 Dec 15].

- Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
8. Merlin VK. Manickavasakam. The combined effect of siddha medicines in the treatment of naakku putru noi (squamous cell carcinoma of the tongue). Int J Pharm Pharm Sci. 2014; 6(1):38-39.
 9. By P, Sanskriti DEV, Mishra A, Batham L, Shrivastava. Yagya Therapy as supportive care in cancer patients improved quality of life : Case studies. Interdiscip J Yagya Res. 2018; 1(1):26-33.
 10. Engdal S, Steinsbekk A, Klepp O. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer. 2008; 16(7):763-769.
 11. Samraj K, Nandhagopal K, Radha S, Rajalakshmi S, Arunachalam K, Annual Report 2019-2020, Siddha Clinical Research Unit, Tirupati 16-24.
 12. Srikumar R, Parthasarathy NJ, Manikandan S, Govindarajulu SN, Rathinasamy S. Effect of Triphala on oxidative stress and on cell-mediated immune response against noise stress in rats. Mol Cell Biochem. 2006; 283:67-74.
 13. Gurjar S, Pal A, Kapur S. Triphala and its constituents ameliorate visceral adiposity from a high-fat diet in mice with diet-induced obesity. Altern Ther Health Med. 2012; 18(6):38-45.
 14. atel DK, Kumar R, Laloo D, Hemalatha S. Diabetes mellitus: An overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. Asian Pac J Trop Biomed. 2012; 2(5):411-420.
 15. Biradar YS, Jagatap S, Khandelwal KR, Singhanian SS. Exploring of antimicrobial activity of TriphalaMashi—An ayurvedic formulation. Evid-Based Comp Altern Med. 2008; 5(1):107-113.
 16. Sandhya T, Lathika KM, Pandey BN, Mishra KP. Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett. 2006; 231(2):206-214.
 17. Naik GH, Priyadarsini KI, Bhagirathi RG, Mishra B, Mishra KP, Banavalikar MM, Mohan H. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. Phytother Res. 2005; 19(7):582-586.
 18. Peterson CT and Denniston K. Therapeutic Uses of Triphala in Ayurvedic Medicine. J alternat complement med. 2017; 23(8):607-614.
 19. Jain J, Narayanan V, Sunil S. In Vivo Evaluation of Withania somnifera – Based Indian Traditional Formulation (Amukkara Choornam), Against Chikungunya Virus – Induced Morbidity and Arthralgia. J Evid-Based Integr Med. 2018; 23:1-7.
 20. Shafreen B and Seema R. Modulatory effects of Amukkara Choornam on Candida albicans biofilm : in vitro and in vivo study. Mol Biol Rep. 2019; 46(3):2961-2969.
 21. Rajalakshmi K, Christian GJ, ShanmugaPriya P, Jeeva Gladys R. Validation of Anti-diabetic Potential of Avirai kudineer a Siddha herbal. IOSR J Dent Med Sci. 2019; 14(7):7-15.
 22. Rajalakshmi K, Shanmugapriya P, Christian GJ. Antimicrobial Potential of Siddha Polyherbal Formulation Aavarai Kudineer. J Pure Appl Microbiol. 2018; 12(2):1019-1025.
 23. Keerthana VAJ (2019). A comparative clinical trial of siddha formulation of nilavaagai chooranam (internally) and thengaai thylam (externally) in the treatment of ‘ karappan ’ (eczema) with and without leech therapy. [Doctoral dissertation, Tamilnadu Dr. MGR Medical University], Institutional repository of Tamilnadu Dr. MGR Medical University, <http://repository-tnmgrmu.ac.in/12129/>.
 24. Ram M, Rao K, Prashbu K. Antioxidant Study and GC MS Analysis of an Ayurvedic Medicine ‘Talisapatradi Choornam. Int J Pharm Sci Rev Res. 2016; 36(1):158-166.
 25. Archana K, Mahadevan MV, Mahalakshmi V, Muthukumar NJ, In vitro pharmacological screening of Parangipattai Kudineer Choornam—a herbal formulation used for Kalanjagapadai (Psoriasis), J Res Biomed Sci, 2(4); 2019: 51-57.
 26. Sudharshini K, Anto S, Saravanan D, Selvaraj R. Antimicrobial Activity of Selected Choornams (Poonaikali, Ponnaravai, Gunma Uppu, Parangipattai) against Drug Resistant Pathogens. Int J Pharm Sci Rev Res. 2017; 46(1):139-145.
 27. Vinodini R, Amala Hazel AM, Meenakshi Sundaram M, Muthukumar NJ. Clinical Evaluation of Parangipattai chooranam (internal) and Annabedhi chenduram (external) for Venpulli (Vitiligo) in children. Res J Pharm Technol. 2019; 12(12): 5932-5936.
 28. Nalini Sofia H, Vetha Merlin KH, Manickavasakam K, Raja Rajeswari P. Efficacy of Karpoora Silasatthu Parpam in The Management Of Azhal Kalladaippu (Renal Calculi). Int. J Adv Res. 2019; 7(2):231-41.
 29. Alam N, Gopal V, Vasanthi C, Manna PK. Nephroprotective potential of Neermulli / Nerunjil Kudineer on Cisplatin induced nephrotoxicity in Wistar albino rats. Int J Res Pharm Sci. 2019; 10(3):1720-1729.
 30. Satish S, Periasamy P, Namasivayam A. Effect of Tribulus terrestris on Experimental Urolithiasis Induced by Ethylene Glycol in Albino Rats. Pharm Sci. 1996; 2(9):437-439.
 31. Jayaraman B, Gnanamani A, Stanley A, Stanley SA. In vivo preclinical evaluation of rasagenthi mezhugu , a siddha formulation , on anti cancer potential in balb / c mice with ct26 murine colon carcinoma. Indo Am J Pharm. 2017; 3(5):266-277.
 32. Álvaro M, Lins DF, Andreia K, Moreno M, Carlos R, Maria S. Constipation prevalence in diabetic patients. J Coloproctol. 2014; 34(2):83-86.
 33. US FDA. Clinical drug interaction studies —cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry (Cited 2020 Oct 18). Available from: <https://www.fda.gov/media/134581/download>.